Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 14 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 20:40 UTC |
Douglass Brian RobbCHIEF PRODUCT OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 675 | $0.00 Strike: $174.86 | $0.00 |
DisclosureSEC source: 0001628280-26-065462 · wk-form4_1791492005.xml · derivative · entry 2 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675 Underlying: Common Stock · 675 shares Expires 2036-10-06 F2 · derivative.exercise_date: 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 20:40 UTC |
Douglass Brian RobbCHIEF PRODUCT OFFICER
|
GrantCommon Stock | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-065462 · wk-form4_1791492005.xml · nonDerivative · entry 1 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,685 F1 · shares: Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,202 | $0.00 Strike: $154.96 | $0.00 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · derivative · entry 4 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,405 Underlying: Common Stock · 4,202 shares Expires 2033-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · derivative.exercise_date: 4,202 shares will vest on October 2, 2027. 4,203 shares will vest on October 2, 2028. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 4,202 | $190.00 | $798,380.00 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 4,202 | $154.96 | $651,141.92 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:18 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 1,333 | $178.75 | $238,273.75 |
DisclosureSEC source: 0001628280-26-065238 · wk-form4_1791317904.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,788 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| October 02, 2026 Filed Oct 5, 2026 20:01 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 1,248 | $181.70 | $226,761.60 |
DisclosureSEC source: 0001628280-26-064889 · wk-form4_1791230479.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,121 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 20:05 UTC | Tax withholdingCommon Stock | 421 | $189.68 | $79,855.28 |
DisclosureSEC source: 0001628280-26-063714 · wk-form4_1790625949.xml · nonDerivative · entry 1 Garland Jason K · CIK 0001754555 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,408 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
|
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,542 | $0.00 Strike: $155.38 | $0.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 6 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,085 Underlying: Common Stock · 4,542 shares Expires 2035-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F3 · derivative.exercise_date: 4,542 shares will vest on March 1, 2027, and 4,543 shares will vest on March 1, 2028. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,404 | $0.00 Strike: $154.96 | $0.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · derivative · entry 5 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,607 Underlying: Common Stock · 8,404 shares Expires 2033-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · derivative.exercise_date: 4,202 shares will vest on each of October 2, 2026, and October 2, 2027. 4,203 shares will vest on October 2, 2028. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 4,542 | $190.00 | $862,980.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 4 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 4,542 | $155.38 | $705,735.96 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 8,404 | $190.00 | $1,596,760.00 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 24, 2026 Filed Sep 25, 2026 20:09 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 8,404 | $154.96 | $1,302,283.84 |
DisclosureSEC source: 0001628280-26-063572 · wk-form4_1790366980.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:07 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,426 | $0.00 Strike: $141.79 | $0.00 |
DisclosureSEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · derivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,426 Underlying: Common Stock · 5,426 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:07 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 5,426 | $180.00 | $976,680.00 |
DisclosureSEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:07 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 5,426 | $141.79 | $769,352.54 |
DisclosureSEC source: 0001628280-26-063026 · wk-form4_1790107640.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 04, 2026 Filed Sep 8, 2026 20:13 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 3,035 | $165.90 | $503,506.50 |
DisclosureSEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,369 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:13 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 2,842 | $169.61 | $482,031.62 |
DisclosureSEC source: 0001628280-26-060911 · wk-form4_1788898417.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,404 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| September 01, 2026 Filed Sep 2, 2026 20:18 UTC |
Hughes ViolettaCHIEF ACCOUNTING OFFICER
|
Tax withholdingCommon Stock | 277 | $170.02 | $47,095.54 |
DisclosureSEC source: 0001628280-26-060105 · wk-form4_1788380307.xml · nonDerivative · entry 2 Hughes Violetta · CIK 0001991429 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,331 F2 · shares: Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:06 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,426 | $0.00 Strike: $141.79 | $0.00 |
DisclosureSEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · derivative · entry 3 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,852 Underlying: Common Stock · 5,426 shares Expires 2034-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. F2 · derivative.exercise_date: 5,426 shares will vest on each of September 3, 2026, and September 3, 2027. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:06 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 5,426 | $180.00 | $976,680.00 |
DisclosureSEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 2 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,246 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 20:06 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 5,426 | $141.79 | $769,352.54 |
DisclosureSEC source: 0001628280-26-058417 · wk-form4_1787342788.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 20:40 UTC | SaleCommon Stock | 530 | $150.00 | $79,500.00 |
DisclosureSEC source: 0001193125-26-307925 · ownership.xml · nonDerivative · entry 1 Garland Jason K · CIK 0001754555 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,829 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025. Read SEC document |
|
| June 25, 2026 Filed Jun 26, 2026 20:05 UTC | SaleCommon Stock | 733 | $145.00 | $106,285.00 |
DisclosureSEC source: 0001193125-26-285449 · ownership.xml · nonDerivative · entry 1 Garland Jason K · CIK 0001754555 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,359 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025. Read SEC document |
|
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Madaus Martin DDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228896 · ownership.xml · derivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Madaus Martin DDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228896 · ownership.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,581 F1 · shares: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Konstantinov KonstantinDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228897 · ownership.xml · derivative · entry 2 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Konstantinov KonstantinDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228897 · ownership.xml · nonDerivative · entry 1 Konstantinov Konstantin · CIK 0001774649 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,889 F1 · shares: Mr. Konstantinov was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
EGLINTON MANNER CARRIEDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228893 · ownership.xml · derivative · entry 2 EGLINTON MANNER CARRIE · CIK 0001696776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
EGLINTON MANNER CARRIEDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228893 · ownership.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,461 F1 · shares: Ms. Manner was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Mhatre RohinDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228888 · ownership.xml · derivative · entry 2 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Mhatre RohinDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228888 · ownership.xml · nonDerivative · entry 1 Mhatre Rohin · CIK 0001798735 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,014 F1 · shares: Mr. Mhatre was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Pax MargaretDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228886 · ownership.xml · derivative · entry 2 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
Pax MargaretDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228886 · ownership.xml · nonDerivative · entry 1 Pax Margaret · CIK 0001999772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,011 F1 · shares: Ms. Pax was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
MUIR GLENN PDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228891 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
MUIR GLENN PDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228891 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,051 F1 · shares: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
DAWES KAREN ADirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228884 · ownership.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
DAWES KAREN ADirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228884 · ownership.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,816 F1 · shares: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
BARTHELEMY NICOLASDirector
|
GrantStock Option (Right to Buy) · Derivative | 2,239 | $0.00 Strike: $103.38 | $0.00 |
DisclosureSEC source: 0001193125-26-228883 · ownership.xml · derivative · entry 2 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,239 Underlying: Common Stock · 2,239 shares Expires 2036-05-14 F2 · derivative.exercise_date: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:05 UTC |
BARTHELEMY NICOLASDirector
|
GrantCommon Stock | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-228883 · ownership.xml · nonDerivative · entry 1 BARTHELEMY NICOLAS · CIK 0001283576 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,436 F1 · shares: Mr. Barthelemy was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| May 07, 2026 Filed May 8, 2026 18:48 UTC |
MUIR GLENN PDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,434 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001193125-26-214293 · ownership.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,434 Underlying: Common Stock · 2,434 shares Expires 2027-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| May 07, 2026 Filed May 8, 2026 18:48 UTC |
MUIR GLENN PDirector
|
Exercise / conversionCommon Stock | 2,434 | $38.76 | $94,341.84 |
DisclosureSEC source: 0001193125-26-214293 · ownership.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2026 Filed May 8, 2026 18:39 UTC |
Douglass Brian RobbCHIEF PRODUCT OFFICER
|
Tax withholdingCommon Stock | 334 | $126.43 | $42,227.62 |
DisclosureSEC source: 0001193125-26-214265 · ownership.xml · nonDerivative · entry 1 Douglass Brian Robb · CIK 0002104618 · CHIEF PRODUCT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,985 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 17:26 UTC |
Loeillot OlivierDirector · Chief Executive Officer
|
SaleCommon Stock | 3,832 | $140.00 | $536,480.00 |
DisclosureSEC source: 0001193125-26-169682 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,246 F1 · price: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on August 19th, 2025. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 16:00 UTC |
KURIYEL RALFSenior VP, R&D
|
GrantStock Option (Right to Buy) · Derivative | 5,669 | $0.00 Strike: $141.91 | $0.00 |
DisclosureSEC source: 0001193125-26-119047 · ownership.xml · derivative · entry 2 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,669 Underlying: Common Stock · 5,669 shares Expires 2036-03-05 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 16:00 UTC |
KURIYEL RALFSenior VP, R&D
|
GrantCommon Stock | 5,284 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-119047 · ownership.xml · nonDerivative · entry 1 KURIYEL RALF · CIK 0001733143 · Senior VP, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,062 F1 · shares: Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 15:53 UTC |
Loeillot OlivierChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,890 | $0.00 Strike: $141.91 | $0.00 |
DisclosureSEC source: 0001193125-26-119036 · ownership.xml · derivative · entry 2 Loeillot Olivier · CIK 0001995525 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,890 Underlying: Common Stock · 25,890 shares Expires 2036-03-05 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 15:53 UTC |
Loeillot OlivierChief Executive Officer
|
GrantCommon Stock | 24,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-119036 · ownership.xml · nonDerivative · entry 1 Loeillot Olivier · CIK 0001995525 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,078 F1 · shares: Mr. Loeillot was awarded 24,134 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| March 05, 2026 Filed Mar 23, 2026 15:53 UTC |
Bylund JamesChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 8,315 | $0.00 Strike: $141.91 | $0.00 |
DisclosureSEC source: 0001193125-26-119034 · ownership.xml · derivative · entry 2 Bylund James · CIK 0001849642 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,315 Underlying: Common Stock · 8,315 shares Expires 2036-03-05 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.